Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 2-9 , February 2007

Cancer Genetics

  • Dianne D. Chapman

      Affiliations

    • Corresponding Author InformationAddress correspondence to Dianne D. Chapman, ND, RN, APRN-C, Rush University Medical Center, 1725 W. Harrison, Suite 821, Chicago, IL 60612-3824

References 

  1. Eisenhaber E, Schleiffer A. The Mendel Site. Historical Heritage: IMP Bioinformatics Group. 2006;Available at http://mendel.imp.ac.at/mendeljsp/index.jsp. (Accessed 8/29/06).
  2. United States Dept of Energy. A historical timeline: Cracking the code of life. Office of Science. 2004;Available at http://www.jgi.doe.gov/education. (Accessed 8/29/06).
  3. Wikipedia. Gregor Johann Mendel; 2006. Available at http://en.wikipedia.org/wiki/Mendel (Accessed 8-26-06).
  4. United States Department of Energy. History of the human genome project: Office of Science. 2006;Available at http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml. (Accessed 8/29/06).
  5. Rieger PT. The biology of cancer genetics. Semin Oncol Nurs. 2004;20:145–154
  6. National Cancer Institute. Visuals online: National Cancer Institute. Available at http://www.cancer.gov/cancertopics/understandingcancer/genetesting. (Accessed 8/29/06).
  7. National Cancer Institute. Available at http://cancer.gov/cancertopics/understandingcancer/cancergenomics. (Accessed 8/29/06).
  8. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005;18:1305–1320
  9. Ensenauer RE, Reinke SS, Ackerman MJ, et al. Primer on medical genomics (Part VIII: Essentials of medical genetics for the practicing physician). Mayo Clin Proc. 2003;78:846–857
  10. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71
  11. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792
  12. Chen Y-C, Hunter DJ. Molecular epidemiology cancer. CA Cancer J Clin. 2005;55:45–54
  13. Lux MP, Ackermann S, Bani MR, et al. Age of uptake of early cancer detection facilities by low-risk and high-risk patients with familial breast and ovarian cancer. Eur J Cancer Prev. 2005;14:503–511
  14. Claus EBJM, Schildkraut JMW, Douglas W, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318–2324
  15. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409–1415
  16. Martin AM, Blackwood MA, Antin-Ozerkis D, et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001;19:2247–2253
  17. Newman B, Millikan RC, King M-C. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev. 1997;19:69–79
  18. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–1408
  19. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23:276–292
  20. Eccles DM. Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. Ann Oncol. 2004;15(suppl 4):iv133–iv138
  21. Thull DL, Vogel VG. Recognition and management of hereditary breast cancer syndromes. Oncologist. 2004;9:13–24
  22. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379–1388
  23. Frank SA. Genetic predisposition to cancer - insights from population genetics. Nature Rev Genet. 2004;5:764–772
  24. Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005;5:388–393
  25. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genetic Couns. 2004;13:83–114
  26. Yong MC, Zhou XJ, Lee SC. The importance of paternal family history in hereditary breast cancer is underappreciated by health care professionals. Oncology. 2003;64:220–226
  27. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. J Clin Oncol. 1996;14:103–110
  28. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1878–1886
  29. Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89:227–238
  30. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Human Genet. 1998;62:145–158
  31. Greco KE, Mahon S. Common hereditary cancer syndromes. Semin Oncol Nurs. 2004;20:164–177
  32. Oncology Nursing Society. Cancer Predisposition Genetic Testing and Risk Assessment Counseling. Pittsburgh, PA: Oncology Nursing Society; 2004;
  33. International Society of Nurses in Genetics (ISONG). Position statement: Informed Decision-Making and Consent: The Role of Nursing: 2005. Available at http://www.isong.org/about/ps_consent.cfm. Pittsburgh, PA; ISONG. (Accessed 8/26/06).
  34. American Society of Clinical Oncology policy statement update: Genetic Testing for Cancer Susceptibility. J Clin Oncol. 2003;21:2397–2406
  35. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: U.S. Preventive Services Task Force Recommendations. Anonymous Ann Intern Med. 2005;143:I–47
  36. U.S. Preventive Services Task Force. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement. Ann Intern Med. 2005;143:355–361
  37. Daly MB, Axilbund JE, Bryant J, et al. Genetic/familial high-risk assessment. J Natl Compr Canc Netw. 2006;4:156–176
  38. Wideroff L, Freedman AN, Olson L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003;12:295–303
  39. Eisen A, Rebbeck TR, Wood WC, et al. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 2000;18:1980–1995
  40. Hartmann LC, Degnim A, Schaid DJ. Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol. 2004;22:981–983
  41. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–1637
  42. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609–1615
  43. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group [see comment]. J Clin Oncol. 2004;22:1055–1062
  44. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–1622
  45. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260–1268
  46. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–2335
  47. Brekelmans CTM, Seynaeve C, Bartels CCM, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol. 2001;19:924–930
  48. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–2741
  49. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23:7804–7810
  50. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA. 2003;289:3243–3253
  51. The Women’s Health Initiative Steering C. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712
  52. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet Gynecol. 2005;106:1327–1334
  53. National Human Genome Research Institute Educational resources: Microarray technology. Available at http://www.genome.gov/Pages/Hyperion/DIR/VIP/Glossary/Illustration/microarray_technology.cfm?keymicroarray%20technology>. (Accessed 8/26/06).
  54. Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11:8623–8631
  55. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  56. Esteban J, Baker J, Cronin M. Tumor gene expression and prognosis in breast cancer: multi-gene RT-PCR assay of paraffin-embedded tissue. [abstract 3416] Proc Am Soc Clin Oncol. 2003;22:417
  57. Paik S, Shak S, Tang G, et al. Genomic Health. Oncotype DX. A multigene RT-PCR assay for predicting the likelihood of breast cancer recurrence. Redwood City, CA: Genomic Health; 2006;
  58. Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med. 1989;320:473–478
  59. National Cancer Institute. The TAILORx breast cancer trial. Available at: http://www.nci.nih.gov/clinicaltrials/digestpage/TAILORx. (Accessed 8/19/06).

PII: S0749-2081(06)00155-0

doi: 10.1016/j.soncn.2006.11.002

Seminars in Oncology Nursing
Volume 23, Issue 1 , Pages 2-9 , February 2007

Article Tools

* Image Usage & Resolution